Shots:
- GSK will invest $163M (€150m) in CureVac for a 10% stake to collaborate for the research, development, manufacturing, and commercialization of up to five mRNA-based vaccines and mAbs targeting infectious disease pathogens excluding CureVac’s existing COVID-19 mRNA and rabies vaccines research programs
- CureVac to receive $137M (€120m) as upfront, $34.3 (€30m) as one-time reimbursable payment and is eligible to receive up to $366M (€320m) as development and regulatory milestones, $435M (€380m) as commercial milestones along with royalties on product sales
- CureVac will lead pre/clinical-development till P-I trial after which GSK will develop & commercialize the therapies. Moreover, CureVAc will receive R&D funding from GSK and will be responsible for the GMP manufacturing of the candidates as well as retain the commercialization rights for all products in selected countries
Click here to read full press release/ article | Ref: GSK | Image: Twitter
